Kiniksa Pharmaceuticals, Ltd.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
424.18 |
631.57 |
767.33 |
910.81 |
1,084.13 |
1,143.50 |
| Przychód Δ r/r |
0.00% |
48.89% |
21.50% |
18.70% |
19.03% |
5.48% |
| Przychód (min) |
423.70 |
621.90 |
715.10 |
910.81 |
1,048.15 |
1,105.55 |
| Przychód (max) |
424.42 |
638.30 |
840.59 |
910.81 |
1,131.54 |
1,193.51 |
| EBITDA (średnia) |
-12.55 |
-18.69 |
-22.71 |
-26.95 |
-32.08 |
-33.84 |
| EBIT (średnia) |
-14.91 |
-22.20 |
-26.98 |
-32.02 |
-38.12 |
-40.20 |
| EBIT % |
-3.52% |
-3.52% |
-3.52% |
-3.52% |
-3.52% |
-3.52% |
| Zysk netto (średni) |
-26.33 |
75.23 |
119.50 |
171.84 |
192.84 |
201.42 |
| Zysk netto % |
-6.21% |
11.91% |
15.57% |
18.87% |
17.79% |
17.61% |
| EPS (średnia) |
-0.39 |
1.05 |
1.64 |
2.12 |
2.70 |
2.82 |
| Liczba analityków (Przychody) |
4 |
4 |
6 |
5 |
1 |
2 |
| Liczba analityków (EPS) |
4 |
3 |
5 |
4 |
3 |
2 |
| symbol |
KNSA |
KNSA |
KNSA |
KNSA |
KNSA |
KNSA |